positive
Recently
Broker Optimism Lifts Ajanta Pharma on Weight Loss Drug Potential
Ajanta Pharma shares rose after Motilal Oswal projected strong gains from its weight loss drug pipeline, citing new product launches, earnings visibility, and up to 17 percent upside potential.
Shares of Ajanta Pharma climbed over 3 percent after Motilal Oswal highlighted strong earnings potential from the company’s upcoming weight loss drug portfolio. The brokerage expects meaningful revenue contribution over the medium term and sees valuation upside driven by new product launches. Investor sentiment improved as analysts factored in growth visibility, strong balance sheet, and Ajanta Pharma’s execution track record.